[{"id":"002fe85e-b3d8-4f4c-9679-0e7ceacd8f48","acronym":"MCC-20963","url":"https://clinicaltrials.gov/study/NCT05177211","created_at":"2022-01-04T13:53:44.017Z","updated_at":"2025-02-25T14:16:34.238Z","phase":"Phase 2","brief_title":"Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)","source_id_and_acronym":"NCT05177211 - MCC-20963","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inrebic (fedratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-02-13"},{"id":"1c457901-9a43-4dcc-9740-e44b1b37ea65","acronym":"NCI-2018-03465","url":"https://clinicaltrials.gov/study/NCT03862157","created_at":"2021-01-18T19:03:08.762Z","updated_at":"2024-07-02T16:35:23.829Z","phase":"Phase 1/2","brief_title":"Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT03862157 - NCI-2018-03465","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR • NPM1 • PDGFRA • PDGFRB • CEBPA","pipe":" | ","alterations":" NPM1 mutation • CEBPA mutation • PDGFRA rearrangement","tags":["ABL1 • BCR • NPM1 • PDGFRA • PDGFRB • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • CEBPA mutation • PDGFRA rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/27/2019","start_date":" 02/27/2019","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-01-10"},{"id":"d12d96b8-74ae-4497-a19e-62e5444280b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01384513","created_at":"2022-01-21T21:56:53.421Z","updated_at":"2024-07-02T16:36:00.226Z","phase":"Phase 2","brief_title":"A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies","source_id_and_acronym":"NCT01384513","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 08/04/2011","start_date":" 08/04/2011","primary_txt":" Primary completion: 11/13/2020","primary_completion_date":" 11/13/2020","study_txt":" Completion: 11/16/2022","study_completion_date":" 11/16/2022","last_update_posted":"2022-11-17"},{"id":"7ef2e0f3-1263-4490-9b0d-ea0be571f605","acronym":"","url":"https://clinicaltrials.gov/study/NCT00489203","created_at":"2021-01-18T01:44:52.854Z","updated_at":"2025-02-25T16:22:35.314Z","phase":"Phase 2","brief_title":"Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","source_id_and_acronym":"NCT00489203","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 04/01/2007","start_date":" 04/01/2007","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":"","study_completion_date":"","last_update_posted":"2021-02-03"},{"id":"eb88bc5b-1f87-4827-bf98-c36dbd9bb4a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02092324","created_at":"2021-01-17T17:18:57.844Z","updated_at":"2024-07-02T16:36:38.667Z","phase":"Phase 2","brief_title":"Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia","source_id_and_acronym":"NCT02092324","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" CSF3R","pipe":" | ","alterations":" CSF3R mutation","tags":["CSF3R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CSF3R mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 07/08/2014","start_date":" 07/08/2014","primary_txt":" Primary completion: 11/22/2019","primary_completion_date":" 11/22/2019","study_txt":" Completion: 01/24/2020","study_completion_date":" 01/24/2020","last_update_posted":"2020-11-16"},{"id":"41a76ca2-10b1-423d-a038-b5e063c28e64","acronym":"","url":"https://clinicaltrials.gov/study/NCT00856388","created_at":"2021-01-18T03:15:49.304Z","updated_at":"2024-07-02T16:36:53.755Z","phase":"","brief_title":"Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders","source_id_and_acronym":"NCT00856388","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" FLT3 • NPM1 • TERT • HLA-DRB1 • DKC1 • TERC","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • NPM1 • TERT • HLA-DRB1 • DKC1 • TERC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 01/14/2009","start_date":" 01/14/2009","primary_txt":" Primary completion: 08/09/2012","primary_completion_date":" 08/09/2012","study_txt":" Completion: 03/13/2019","study_completion_date":" 03/13/2019","last_update_posted":"2019-11-13"},{"id":"5ff22ee6-6c95-4b3e-80e2-eb69bcdf6c52","acronym":"","url":"https://clinicaltrials.gov/study/NCT01199562","created_at":"2021-01-18T04:48:21.624Z","updated_at":"2025-02-25T16:23:31.204Z","phase":"","brief_title":"Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant","source_id_and_acronym":"NCT01199562","lead_sponsor":"City of Hope Medical Center","biomarkers":" NCAM1 • LAMP2","pipe":"","alterations":" ","tags":["NCAM1 • LAMP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Valcyte (valganciclovir)"],"overall_status":"Completed","enrollment":" Enrollment 153","initiation":"Initiation: 12/01/2010","start_date":" 12/01/2010","primary_txt":" Primary completion: 12/01/2013","primary_completion_date":" 12/01/2013","study_txt":" Completion: 12/01/2013","study_completion_date":" 12/01/2013","last_update_posted":"2019-04-25"},{"id":"7778f5d4-6d5a-4b6e-8cc1-927aa852f355","acronym":"","url":"https://clinicaltrials.gov/study/NCT00112593","created_at":"2021-01-18T00:22:32.319Z","updated_at":"2025-02-25T16:21:57.663Z","phase":"","brief_title":"Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer","source_id_and_acronym":"NCT00112593","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 11/01/1999","start_date":" 11/01/1999","primary_txt":" Primary completion: 11/01/2014","primary_completion_date":" 11/01/2014","study_txt":"","study_completion_date":"","last_update_posted":"2017-05-24"}]